SCHEMBL17602847

SCHEMBL17602847

O=C(O)N1CCC/C(=C\c2cc(F)ccc2S(=O)(=O)Cl)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 3/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ NOD2 Q9HC29 1/20 0.34
▸ SRD5A2 P31213 4/20 0.34
▸ DPP4 P27487 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ DPP7 Q9UHL4 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ AKR1C3 P42330 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ PER2 O15055 2/20 0.32
▸ CRY2 Q49AN0 1/20 0.32
▸ CHRM2 P08172 1/20 0.32
▸ CHRM3 P20309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15667982 1.00 HTT (0.34) HTTSMN1; SMN2LMNANOD2SRD5A2
SCHEMBL15667961 0.86 ESR2 (0.40) —
SCHEMBL17602758 0.86 ESR2 (0.40) —
SCHEMBL6082641 0.76 ALDH1A1 (0.46) LMNASRD5A2ALDH1A1
SCHEMBL6082644 0.76 ALDH1A1 (0.46) LMNASRD5A2ALDH1A1
SCHEMBL13738308 0.74 NFE2L2 (0.46) SMN1; SMN2ALDH1A1MAPTPOLBHPGD
SCHEMBL15608176 0.74 NFE2L2 (0.46) SMN1; SMN2ALDH1A1MAPTPOLBHPGD
SCHEMBL17602763 0.70 CHRNB2 (0.43) —
SCHEMBL15667965 0.70 CHRNB2 (0.43) —
SCHEMBL19772992 0.70 CHRNB2 (0.43) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9868717-B2 Tricyclic sulphonamide compounds and methods of making and using same ZAFGEN, INC. (US) 2018-01-16 — — US disclosed
EP-2925737-B1 TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY ZAFGEN INC (US) 2017-06-14 — — EP disclosed
US-20160083362-A1 TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. 2016-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160083362-A1 TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME DNPEP, ANPEP, METAP2 HTT 824/4885SMN1; SMN2 3417/4885LMNA 3870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback